These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1113 related articles for article (PubMed ID: 19193585)

  • 21. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
    Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
    Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chemotherapy for multiple myeloma].
    Ishida T
    Nihon Rinsho; 2007 Dec; 65(12):2280-4. PubMed ID: 18069273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment paradigms for the newly diagnosed patient with multiple myeloma.
    Greipp P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S16-21. PubMed ID: 16344097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
    Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M
    J Clin Oncol; 2010 Dec; 28(34):5101-9. PubMed ID: 20940200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
    Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
    Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.
    Björkstrand B; Gahrton G
    Semin Hematol; 2007 Oct; 44(4):227-33. PubMed ID: 17961721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
    Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in myeloma treatment.
    Schots R
    Transfus Apher Sci; 2011 Apr; 44(2):223-9. PubMed ID: 21349768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
    Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
    Palumbo A; Avonto I; Bruno B; Falcone A; Scalzulli PR; Ambrosini MT; Bringhen S; Gay F; Rus C; Cavallo F; Falco P; Massaia M; Musto P; Boccadoro M
    Clin Lymphoma Myeloma; 2006 May; 6(6):475-7. PubMed ID: 16796778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment options for relapsed and refractory multiple myeloma.
    Lonial S; Mitsiades CS; Richardson PG
    Clin Cancer Res; 2011 Mar; 17(6):1264-77. PubMed ID: 21411442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma.
    Barosi G; Merlini G; Billio A; Boccadoro M; Corradini P; Marchetti M; Massaia M; Tosi P; Palumbo A; Cavo M; Tura S
    Ann Hematol; 2012 Jun; 91(6):875-88. PubMed ID: 22476884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrating novel therapies in the transplant paradigm.
    Harousseau JL
    Cancer J; 2009; 15(6):479-84. PubMed ID: 20010167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New treatment strategy of multiple myeloma for cure].
    Murakami H; Handa H
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of transplant-eligible symptomatic multiple myeloma].
    Nakaseko C
    Rinsho Ketsueki; 2014 Oct; 55(10):2016-26. PubMed ID: 25297767
    [No Abstract]   [Full Text] [Related]  

  • 36. Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.
    Chim CS; Choi PT; Lee WK
    Ann Hematol; 2013 Jun; 92(6):855-7. PubMed ID: 23183880
    [No Abstract]   [Full Text] [Related]  

  • 37. Current therapeutic strategy for multiple myeloma.
    Suzuki K
    Jpn J Clin Oncol; 2013 Feb; 43(2):116-24. PubMed ID: 23293370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted treatments to improve stem cell outcome: old and new drugs.
    Raab MS; Breitkreutz I; Anderson KC
    Bone Marrow Transplant; 2007 Dec; 40(12):1129-37. PubMed ID: 17768392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging drugs in multiple myeloma.
    Ghobrial IM; Leleu X; Hatjiharissi E; Hideshima T; Mitsiades C; Schlossman R; Anderson KC; Richardson P
    Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.